MeiraGTx Holdings PLC MGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MGTX is a good fit for your portfolio.
News
-
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
-
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
-
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
-
MeiraGTx shares jump as Sanofi invests in gene therapy
-
MeiraGTx Gets $30 Million Investment From Sanofi
Trading Information
- Previous Close Price
- $5.01
- Day Range
- $4.89–5.12
- 52-Week Range
- $3.49–8.35
- Bid/Ask
- $5.08 / $5.09
- Market Cap
- $326.87 Mil
- Volume/Avg
- 185,733 / 152,910
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.19
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 419
- Website
- https://www.meiragtx.com
Comparables
Valuation
|
Metric
|
MGTX
|
ZURA
|
02181
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.31 | 2.70 | 11.53 |
Price/Sales | 20.19 | — | 18.17 |
Price/Cash Flow | — | — | — |
Price/Earnings
MGTX
ZURA
02181
Financial Strength
|
Metric
|
MGTX
|
ZURA
|
02181
|
|---|---|---|---|
Quick Ratio | 2.28 | 4.92 | 0.69 |
Current Ratio | 2.38 | 4.97 | 1.08 |
Interest Coverage | −5.52 | — | −20.87 |
Quick Ratio
MGTX
ZURA
02181
Profitability
|
Metric
|
MGTX
|
ZURA
|
02181
|
|---|---|---|---|
Return on Assets (Normalized) | −39.28% | −71.08% | −20.43% |
Return on Equity (Normalized) | −105.66% | −139.85% | −79.65% |
Return on Invested Capital (Normalized) | −52.99% | −99.89% | −38.37% |
Return on Assets
MGTX
ZURA
02181
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fgxnlcwmh | Wxp | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mlmtfrpt | Flwhfz | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rklkrtw | Ccltrb | $98.1 Bil | |
MRNA
| Moderna Inc | Zxjglbsr | Swcwr | $39.1 Bil | |
ARGX
| argenx SE ADR | Ngptvybf | Ksm | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Zctngpcv | Jqmlc | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jnqlfpmf | Hxtrfd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ptszyfgmp | Bfqjjk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jnpygbsqv | Smqfpvf | $12.5 Bil | |
INCY
| Incyte Corp | Btrpnxcjv | Gtpcd | $11.9 Bil |